Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Description

This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.

Conditions

Primary Sclerosing Cholangitis

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.

A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)

Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis

Condition
Primary Sclerosing Cholangitis
Intervention / Treatment

-

Contacts and Locations

Chestnut Hill

Brigham and Women's Hospital, Chestnut Hill, Massachusetts, United States, 02467

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age 15-80
  • 2. A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP) demonstrating intrahepatic and/or extrahepatic biliary strictures, beading or irregularity consistent with PSC.
  • 3. ALP \> 1.67 times the upper limit of normal (ULN) at screening
  • 4. Inflammatory bowel disease
  • 5. Subject must either be on a stable dose of ursodeoxycholic acid for \> 6 months prior to screening or have been discontinued \> 4 weeks prior to screening (enrollment of patients who are on UDCA will be limited to 50% of all enrolled patients).
  • 1. Anticipated need for liver transplant within one year as determined by Mayo PSC risk score treatment
  • 2. Evidence of decompensated liver disease such as variceal bleeding, ascites, or hepatic encephalopathy.
  • 3. Evidence of advanced liver disease including MELD score \> 10, bilirubin \> 3.0, platelet count \< 100,000; or INR \> 1.4
  • 4. Concomitant chronic liver disease including alcohol related liver disease, chronic hepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsin deficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliary cholangitis
  • 5. Secondary causes of sclerosing cholangitis
  • 6. Known intolerance to sulfasalazine (including but not limited to allergy to sulfa or mesalamine) or folic acid
  • 7. History of cholangiocarcinoma or colon cancer within 5 years
  • 8. History of colectomy with \> 1/3 bowel resected
  • 9. Treatment with any investigational agents, within two months or 5 half-lives of the investigational product, whichever is longer.
  • 10. Active illicit drug or alcohol abuse
  • 11. Current or past use of sulfasalazine within 6 months of enrollment.
  • 12. Need for chronic use of antibiotics
  • 13. Evidence of bacterial cholangitis within 6 months of enrollment
  • 14. In patients with Ulcerative Colitis, simple clinical colitis activity index of \> 4 or, if Crohn's disease, a Harvey-Bradshaw index of \> 5
  • 15. Chronic kidney injury (eGFR \< 59)
  • 16. Pregnancy or lactation

Ages Eligible for Study

15 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Brigham and Women's Hospital,

Joshua R Korzenik, MD, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

2024-11-01